Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes

mAbs

Volumn 4, Issue 5, 2012, Pages 553-554

  Pandey, Janardan P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CETUXIMAB; CHIMERIC ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; LEUCINE; OLIGOSACCHARIDE; PANITUMUMAB; PHENYLALANINE; VALINE;

ALLELE; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGENICITY; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; COLORECTAL CANCER; EDITORIAL; HEMAGGLUTINATION INHIBITION; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; TRANSFUSION;

ANIMALS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE; HUMANS; IMMUNOGLOBULIN GM ALLOTYPES; MICE;

EID: 84866538709     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.21311     Document Type: Editorial

References (14)

1. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221-3; PMID:22270724; http://dx.doi.org/10.1038/nm.2609.
2. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532-6; http://dx.doi. org/10.1038/ nature11156; PMID:22722830.
3. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3:99ra86; http://dx.doi.org/10.1126/scitranslmed.3002442; PMID:21900593.
4. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009; 1:332-8; PMID:20073133; http://dx.doi.org/10.4161/mabs.1.4.9122.
5. Grubb R. Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 1995; 12:191-7; PMID:8534505.
6. Fudenberg HH, Fudenberg BR. Antibody to hereditary human gamma-globulin (Gm) factor resulting from maternal-fetal incompatibility. Science 1964; 145:170-1; PMID:14171557; http://dx.doi.org/10.1126/science. 145.3628.170.
7. Morahan G, Berek C, Miller JFAP. An idiotypic determinant formed by both immunoglobulin constant and variable regions. Nature 1983; 301:720-2; PMID:6186921; http://dx.doi.org/10.1038/301720a0.
8. Casadevall A, Pirofski L-A. A new synthesis for antibody-mediated immunity. Nat Immunol 2012; 13:21-8; PMID:22179281; http://dx.doi.org/10.1038/ ni.2184.
9. Torres M, Fernández-Fuentes N, Fiser A, Casadevall A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 2007; 282:13917-27; PMID:17353196; http://dx.doi.org/10.1074/jbc.M700661200.
10. Grubb R. The Genetic Markers of Human Immunoglobulins. New York, NY, Springer-Verlag Press, 1970.
11. Schanfield MS, van Loghem E. Human immunoglobulin allotypes. In: Weir DM, editor. Handbook of Experimental Immunology. Boston, MA, Blackwell Press, 94.1-94.18, 1986.
12. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008; 358:1109-17; PMID:18337601; http://dx.doi.org/10. 1056/NEJMoa074943.
13. Daguet A, Watier H. 2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. MAbs 2011; 3:417-21; PMID:21857165; http://dx.doi.org/10.4161/mabs.3.5. 17485.
14. van Loghem E, Aalberse RC, Matsumoto H. A genetic marker of human IgE heavy chains, Em(1). Vox Sang 1984; 46:195-206; PMID:6201004; http://dx.doi. org/10.1111/j.1423-0410.1984.tb00075.x.